[Revision of the treatment strategy in Parkinson disease].
D000547:Amantadine / Q000627:therapeutic use; D000978:Antiparkinson Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D001971:Bromocriptine / Q000627:therapeutic use; D002262:Carboxy-Lyases / Q000037:antagonists & inhibitors; D006801:Humans; D007980:Levodopa / Q000627:therapeutic use; D008996:Monoamine Oxidase Inhibitors / Q000627:therapeutic use; D010300:Parkinson Disease / Q000188:drug therapy*; D010347:Patient Care Planning
D000978:Antiparkinson Agents; D008996:Monoamine Oxidase Inhibitors; D001971:Bromocriptine; D007980:Levodopa; D000547:Amantadine; D002262:Carboxy-Lyases
Behandelingsstrategie bij de ziekte van Parkinson herzien.